LBA2_PR: Osimertinib (AZD9291) in pre-treated pts with T790M-positive advanced NSCLC: updated Phase 1 (P1) and pooled Phase 2 (P2) results

Journal of Thoracic Oncology

Volumn 11, Issue 4, 2016, Pages S152-S153

  Yang, J ^a   Ramalingam, S S ^b   Janne P A ^c   Cantarini, M ^d   Mitsudomi, T ^e  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d ASTRAZENECA   (United Kingdom)

^e KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

OSIMERTINIB;

ADVANCED CANCER; ARTICLE; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CAUSAL ATTRIBUTION; CLINICAL EFFECTIVENESS; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; HUMAN; MAJOR CLINICAL STUDY; NON SMALL CELL LUNG CANCER; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; POPULATION RESEARCH; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; SURVIVAL TIME;

EID: 85000962707     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1016/S1556-0864(16)30325-2     Document Type: Article

References (0)